Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Is It Reactive or IBD-Associated Arthritis?

Hanan Ibrahim, MD, Weixia Guo, MD, & Ayad Alkhatib, MD  |  Issue: January 2021  |  January 19, 2021

Discussion

Inflammatory bowel disease-related arthropathy is classified into two types: type 1 is related to disease activity, typically affecting fewer than five large joints. It is usually acute, self-limiting and responds well to inflammatory bowel disease-related treatment in most cases. 

Type 2 is more chronic and remains for years; in some cases, it has been associated more with uveitis.2 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Because our patient’s symptoms were relatively acute, his arthritis would more likely be classified as type 1; however, because he was on infliximab, we would expect the arthritis to be under control. It’s possible that infliximab was not enough to control his inflammatory bowel disease symptoms, and therefore, he had persistent diarrhea and inflammatory bowel disease arthropathy.

It’s important to consider other possible etiologies of the patient’s arthritis, including reactive arthritis. There are two major types of reactive arthritis, depending on the causative organism. The first type is related to post-enteric infections, classically described with Salmonella, Shigella, Campylobacter and Yersinia. The second type is associated with post-venereal infections, mostly Chlamydia trachomatis.3 Lately, C. difficile infection has been implicated as a less common causative organism.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

C. difficile infection is the most common gastrointestinal infection in patients with inflammatory bowel disease.4 According to recent literature, the prevalence of C. difficile infection has increased in the past decade, and it has been associated with worse prognosis and outcomes.5 In this patient, a diagnosis of C. difficile infection-associated reactive arthritis spared him unnecessary changes in his immunosuppressive treatment plan. 

This case was challenging because the patient also had a history of complicated inflammatory bowel disease, raising a suspicion for possible inflammatory bowel disease-related arthritis. However, his condition was controlled, making that diagnosis less likely. Given the patient’s ongoing diarrhea while undergoing aggressive treatment with infliximab, his immunosuppressed state, elevated inflammatory markers, the elevation of his white blood cell counts and the evidence of C. difficile infection in the setting of large joint oligoarthritis in a young adult, reactive arthritis was a more likely diagnosis.6

Conclusion

We described a challenging case of a young man who was referred for consultation of possible newly developed inflammatory bowel disease-related arthritis. On evaluation, he was found to have reactive arthritis secondary to C. difficile infection, which is a rare but well-recognized causative agent for this condition. 

This case highlights the importance of keeping an open mind and considering a broad range of possible diagnoses when evaluating rare and complicated conditions, integrating different elements of a patient’s historical information and current workup. Clinicians should maintain a high index of suspicion for rare manifestations of common etiologies.

Page: 1 2 3 | Single Page
Share: 

Filed under:Axial SpondyloarthritisConditions Tagged with:case reportCrohn's diseaseInfectioninflammatory bowel disease (IBD)Reactive arthritis

Related Articles

    Case Report: Reactive Arthritis Following COVID-19

    September 14, 2021

    SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

    Research Provides Insight into Impact of Microbiome on Health, Rheumatic Disease

    April 15, 2016

    The microbiome comprises diverse microbial flora, including bacteria, viruses and fungi, that live on mucosal surfaces, predominantly the skin and digestive tract. Microbes evolved billions of years prior to the development of modern Homo sapiens 200,000 years ago; we have always existed with their ubiquitous presence. Despite this, the first microbe was not visualized until…

    Fellow’s Forum Case Report: Arthritis, Fever, and Weight Loss In a Teenager Suggest A Rheumatic Condition

    January 1, 2014

    Joint pain and swelling flare up in a 14-year-old boy who tests positive for inflammation, thrombocytosis, and human leukocyte antigen B27

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences